Is ibrutinib a targeted drug?

Ibrutinib is a targeted drug. Ibrutinib is a small molecule drug that irreversibly binds to proteinBruton’s tyrosine kinase(BTK ), inhibits B cell proliferation and survival. Blocking BTKinhibits the B cell receptor pathway, which is often hyperactive in B cell carcinomas. Therefore, ibrutinib is used to treat this type of cancer, including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenströ's macroglobulinemia. Ibrutinib also binds to Cterminal Srckinase. These are non-target receptors for BTK inhibitors. Ibrutinib binds to these receptors and inhibits the kinases to promote cell differentiation and growth, which results in many different side effects, such as left atrial enlargement and atrial fibrillation during treatment of chronic lymphocytic leukemia.

Ibrutinib is a potent, irreversible inhibitor of Bruton tyrosine kinase (BTK). The acrylamide group of ibrutinib forms a covalent bond with the cysteine u200bu200bresidue C481 in the BTK active site, resulting in sustained inhibition of BTK enzyme activity. BTK is an important signaling molecule in the B cell antigen receptor (BCR) pathway. It plays a role in the pathogenesis of several B cell malignant tumors, including MTK lymphocytic lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, and chronic lymphocytic leukemia (CLL). Preclinical studies have shown that ibrutinib can effectively inhibit malignant B cells proliferation and survival in vivo, as well as cell migration and matrix adhesion in vitro. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.